Fig. 6: Low dose of RIF sensitizes SKOV3-derived xenograft tumors to olaparib in vivo.
From: Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
A Female BALB/c nude mice bearing luciferized SKOV3-derived tumors were randomized into four treatment groups and treated with vehicle control, low dose of RIF (135 mg/kg, daily by i.g.), olaparib (100 mg/kg, daily by i.g.), or RIF/olaparib combination for each model till 3 weeks (n = 8 mice per group). Tumor growth was monitored by weekly bioluminescence imaging of the mice. Representative images of mice bearing SKOV3 xenografts. B Tumor burden at the end of the treatment is represented as mean ± SD. C Representative images of the abdominal tumor nodules in colon, spleen, and liver in the four different treated groups are shown. D Tumors dissected from the SKOV3 xenografts with the indicated treatments were examined for Ki-67 protein expression by IHC and HE staining. Scale bar, 100 μm. *P < 0.05; **P < 0.01.
